… and bleeding risk with dabigatran and warfarin, but in the present study we focus only on …
In this nationwide cohort study, we found that for patients with a history of stroke/transient …

… Our study is not a randomized trial but is a nationwide cohort study sized with a case and …
Our strength is the 4,086 patient-year experience with dabigatran treatment from this first “…

… of dabigatran, a novel oral anticoagulant, provided a new treatment option for stroke prevention
in atrial fibrillation beyond warfarin, … among patient demographic and clinical subgroups. …

… We performed a retrospective population-based cohort study to determine the incidence of
bleeding in patients with atrial fibrillation (AF) beginning dabigatran, rivaroxaban or warfarin. …

… Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial
fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61:2264-73. doi:…

… The aim of this study was to assess the association between the use … dabigatran, rivaroxaban,
and apixaban and the risk of stroke or SE and bleeding in a nationwide cohort of patients …

… on patients receiving standard dosages of apixaban, dabigatran, and rivaroxaban, because
… These two classifications represented primary and secondary prevention treatment groups, …

… This study used a similar design to ours and saw more events, but it included only … by
dabigatran dose (24). Finally, outside of our study, separate analyses of dabigatran versus warfarin …

… In our nationwide cohort study of 31 522 OAC-naïve AF patients initiating NOAC treatment,
the associated stroke risks were similar in comparison with standard dose NOACs or in …

… nationwide population-based cohort study showed that NOACs were superior to warfarin for
the secondary prevention … standard-dose NOAC users (dabigatran 150 mg bid, rivaroxaban …